Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Targets |
H1N1(IC50= 70 nM)
|
---|---|
ln Vitro |
CBS1117 exhibits an excellent antiviral selectivity index value (SI value of 3914) in the human lung epithelial cell line (A549), owing to its higher CC50 value of 274 μM and lower IC50 value of 70 nM[1].
|
References |
Molecular Formula |
C15H20CL2N2O
|
---|---|
Molecular Weight |
315.238101959229
|
CAS # |
959245-08-0
|
SMILES |
ClC1C=CC=C(C=1C(NC1CCN(C(C)C)CC1)=O)Cl
|
InChi Key |
OUZZSIOQTSNTTI-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C15H20Cl2N2O/c1-10(2)19-8-6-11(7-9-19)18-15(20)14-12(16)4-3-5-13(14)17/h3-5,10-11H,6-9H2,1-2H3,(H,18,20)
|
Chemical Name |
2,6-dichloro-N-(1-propan-2-ylpiperidin-4-yl)benzamide
|
Synonyms |
CHEMBL4438419; SCHEMBL24665417; DTXSID101198257; CBS-1117; STK492633;
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~250 mg/mL (~793.05 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.1722 mL | 15.8609 mL | 31.7219 mL | |
5 mM | 0.6344 mL | 3.1722 mL | 6.3444 mL | |
10 mM | 0.3172 mL | 1.5861 mL | 3.1722 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
The specificity and inhibitory effect of the seven compounds on pseudo and infectious virus.[1].Antiviral Res. 2020 May;177:104782. td> |
CBS1116 is group 1 IAV specific inhibitor.[1].Antiviral Res. 2020 May;177:104782. td> |
Time of addition experiment.[1].Antiviral Res. 2020 May;177:104782. td> |
Effects of CBS1116 on HA binding to cell surface and HA-mediated fusion process.[1].Antiviral Res. 2020 May;177:104782. td> |
Structure activity relationship (SAR) developed for CBS1116. [1].Antiviral Res. 2020 May;177:104782. td> |